Literature DB >> 20812336

Insulin-like growth factor 1 synergizes with bone morphogenetic protein 7-mediated anabolism in bovine intervertebral disc cells.

Jae-Sung Kim1, Michael B Ellman, Howard S An, Andre J van Wijnen, Jeffrey A Borgia, Hee-Jeong Im.   

Abstract

OBJECTIVE: We undertook this study to assess the therapeutic benefits of intervertebral disc matrix repair and regeneration by evaluating the potential synergistic effect of insulin-like growth factor 1 (IGF-1) and bone morphogenetic protein 7 (BMP-7) on bovine spine discs and by elucidating the relevant molecular/cellular mechanisms.
METHODS: Bovine nucleus pulposus (NP) cells were treated with BMP-7 and IGF-1. The subsequent anabolic effects driven by NP cells were assessed for proteoglycan (PG) synthesis by (35) S-sulfate incorporation and for PG accumulation by dimethylmethylene blue assays. Matrix formation was visualized by particle exclusion assay. Key matrix components and transcription factors were analyzed by real-time reverse transcription-polymerase chain reaction to determine the signaling pathways by which IGF-1 suppresses noggin, a potent inhibitor of BMP-7. Western blotting and nuclear translocation experiments were performed to assess the activation of Smad proteins.
RESULTS: Stimulation of bovine NP cells by both IGF-1 and BMP-7 greatly potentiated anabolism through complementary and synergistic mechanisms on matrix formation compared with treatment with either growth factor alone. The exogenously added decoy ligand, noggin, attenuated the anabolic effects of BMP-7, and noggin was substantially increased by BMP-7, suggesting a negative feedback regulatory mechanism. In contrast, IGF-1 significantly suppressed noggin expression via the phosphatidylinositol 3-kinase/Akt pathway and thus potentiated BMP-7 signaling in bovine NP cells. Upon combination treatment, IGF-1 activated Smad2, while BMP-7 activated Smad1/5/8 and Smad3, thus inducing all Smad signaling pathways and mimicking the effects of the combination of transforming growth factor β and BMP-7
CONCLUSION: Combination growth factor therapy using BMP-7 and IGF-1 may have considerable promise in the treatment of spine disc degeneration.
Copyright © 2010 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20812336      PMCID: PMC2995823          DOI: 10.1002/art.27733

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  44 in total

1.  Osteogenic protein-1 enhances matrix replenishment by intervertebral disc cells previously exposed to interleukin-1.

Authors:  Kenji Takegami; Eugene J M A Thonar; Howard S An; Hiroshi Kamada; Koichi Masuda
Journal:  Spine (Phila Pa 1976)       Date:  2002-06-15       Impact factor: 3.468

2.  Summary statement: emerging techniques for treatment of degenerative lumbar disc disease.

Authors:  Howard An; Scott D Boden; James Kang; Harvinder S Sandhu; William Abdu; James Weinstein
Journal:  Spine (Phila Pa 1976)       Date:  2003-08-01       Impact factor: 3.468

3.  The IGF-I receptor in cell growth, transformation and apoptosis.

Authors:  R Baserga; A Hongo; M Rubini; M Prisco; B Valentinis
Journal:  Biochim Biophys Acta       Date:  1997-06-07

4.  Three-dimensional culture of human disc cells within agarose or a collagen sponge: assessment of proteoglycan production.

Authors:  Helen E Gruber; Gretchen L Hoelscher; Kelly Leslie; Jane A Ingram; Edward N Hanley
Journal:  Biomaterials       Date:  2005-08-11       Impact factor: 12.479

Review 5.  The control of chondrogenesis.

Authors:  Mary B Goldring; Kaneyuki Tsuchimochi; Kosei Ijiri
Journal:  J Cell Biochem       Date:  2006-01-01       Impact factor: 4.429

6.  Anti-apoptotic effects of IGF-1 and PDGF on human intervertebral disc cells in vitro.

Authors:  H E Gruber; H J Norton; E N Hanley
Journal:  Spine (Phila Pa 1976)       Date:  2000-09-01       Impact factor: 3.468

7.  Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis of cartilage proteoglycans and collagens by human articular chondrocytes.

Authors:  J Flechtenmacher; K Huch; E J Thonar; J A Mollenhauer; S R Davies; T M Schmid; W Puhl; T K Sampath; M B Aydelotte; K E Kuettner
Journal:  Arthritis Rheum       Date:  1996-11

8.  Insulin-like growth factors maintain steady-state metabolism of proteoglycans in bovine articular cartilage explants.

Authors:  F P Luyten; V C Hascall; S P Nissley; T I Morales; A H Reddi
Journal:  Arch Biochem Biophys       Date:  1988-12       Impact factor: 4.013

Review 9.  The pathophysiology of osteoarthritis.

Authors:  Florenzo Iannone; Giovanni Lapadula
Journal:  Aging Clin Exp Res       Date:  2003-10       Impact factor: 3.636

10.  Growth factor osteogenic protein-1: differing effects on cells from three distinct zones in the bovine intervertebral disc.

Authors:  Yejia Zhang; Howard S An; Shiwen Song; Marc Toofanfard; Koichi Masuda; Gunnar B J Andersson; Eugene J M A Thonar
Journal:  Am J Phys Med Rehabil       Date:  2004-07       Impact factor: 2.159

View more
  23 in total

Review 1.  Molecular basis of intervertebral disc degeneration and herniations: what are the important translational questions?

Authors:  Tiffany Kadow; Gwendolyn Sowa; Nam Vo; James D Kang
Journal:  Clin Orthop Relat Res       Date:  2015-06       Impact factor: 4.176

2.  MicroRNA-146a reduces IL-1 dependent inflammatory responses in the intervertebral disc.

Authors:  Su-Xi Gu; Xin Li; John L Hamilton; Ana Chee; Ranjan Kc; Di Chen; Howard S An; Jae-Sung Kim; Chun-do Oh; Yuan-Zheng Ma; Andre J van Wijnen; Hee-Jeong Im
Journal:  Gene       Date:  2014-10-12       Impact factor: 3.688

3.  Coumestrol Counteracts Interleukin-1β-Induced Catabolic Effects by Suppressing Inflammation in Primary Rat Chondrocytes.

Authors:  Jae-Seek You; In-A Cho; Kyeong-Rok Kang; Ji-Su Oh; Sang-Joun Yu; Gyeong-Je Lee; Yo-Seob Seo; Su-Gwan Kim; Chun Sung Kim; Do Kyung Kim; Hee-Jeong Im; Jae-Sung Kim
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

4.  Downregulation of microRNA-193a-3p is involved in invertebral disc degeneration by targeting MMP14.

Authors:  Ming-Liang Ji; Xue-Jun Zhang; Pei-Liang Shi; Jun Lu; Shan-Zheng Wang; Qing Chang; Hui Chen; Chen Wang
Journal:  J Mol Med (Berl)       Date:  2015-12-01       Impact factor: 4.599

5.  Osteoarthritic tissues modulate functional properties of sensory neurons associated with symptomatic OA pain.

Authors:  Xin Li; Jae-Sung Kim; Andre J van Wijnen; Hee-Jeong Im
Journal:  Mol Biol Rep       Date:  2011-02-16       Impact factor: 2.316

6.  Toll-like receptor adaptor signaling molecule MyD88 on intervertebral disk homeostasis: in vitro, ex vivo studies.

Authors:  Michael B Ellman; Jae-Sung Kim; Howard S An; Di Chen; Ranjan KC; Jennifer An; Teju Dittakavi; Andre J van Wijnen; Gabriella Cs-Szabo; Xin Li; Guozhi Xiao; Steven An; Su-Gwan Kim; Hee-Jeong Im
Journal:  Gene       Date:  2012-06-10       Impact factor: 3.688

7.  Noggin is novel inducer of mesenchymal stem cell adipogenesis: implications for bone health and obesity.

Authors:  Anandi Sawant; Diptiman Chanda; Tatyana Isayeva; George Tsuladze; W T Garvey; Selvarangan Ponnazhagan
Journal:  J Biol Chem       Date:  2012-02-20       Impact factor: 5.157

8.  Lactoferricin mediates anti-inflammatory and anti-catabolic effects via inhibition of IL-1 and LPS activity in the intervertebral disc.

Authors:  Jae-Sung Kim; Michael B Ellman; Dongyao Yan; Howard S An; Ranjan Kc; Xin Li; Di Chen; Guozhi Xiao; Gabriella Cs-Szabo; David W Hoskin; Doug D Buechter; Andre J Van Wijnen; Hee-Jeong Im
Journal:  J Cell Physiol       Date:  2013-09       Impact factor: 6.384

9.  Lactoferricin enhances BMP7-stimulated anabolic pathways in intervertebral disc cells.

Authors:  Michael B Ellman; Jaesung Kim; Howard S An; Di Chen; Ranjan Kc; Xin Li; Guozhi Xiao; Dongyao Yan; Joon Suh; Andre J van Wijnen; James H-C Wang; Su-Gwan Kim; Hee-Jeong Im
Journal:  Gene       Date:  2013-04-30       Impact factor: 3.688

10.  Molecular and genetic advances in the regeneration of the intervertebral disc.

Authors:  Tristan Maerz; Harry Herkowitz; Kevin Baker
Journal:  Surg Neurol Int       Date:  2013-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.